Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort

 

Nothing here helps stroke survivors prevent Parkinsons post stroke. No definition of highest or if it is truly the caffeine or all the other micronutrients in coffee.

Benefits Aren't Just From Caffeine December 2018

With your risk of Parkinsons post stroke, your competent doctor should be ready with EXACT AMOUNTS TO CONSUME! Or don't you have a competent doctor?

Parkinson’s Disease May Have Link to Stroke March 2017

 

Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort

Yujia Zhao, MSc https://orcid.org/0000-0002-5275-0036, Yunjia Lai, PhD https://orcid.org/0000-0002-1081-0897, Hilde Konijnenberg, MSc, José María Huerta, PhD, Ana Vinagre-Aragon, MD, Jara Anna Sabin, Johnni Hansen, PhD, … Show All … , and Roel Vermeulen, PhDAuthors Info & Affiliations

April 23, 2024 issue

102 (8)

https://doi.org/10.1212/WNL.0000000000209201

• 
  

• • Abstract
  • Introduction
  • Methods
  • Results
  • Discussion
  • Glossary
  • Acknowledgment
  • Study Funding
  • Disclosure
  • Publication History
  • Appendix Authors
  • Supplementary Material
  • References
• • Information & Authors
  • Metrics & Citations
  • View Options
  • References
  • Media
  • Tables
  • Share

Abstract

Background and Objectives

Inverse associations between caffeine intake and Parkinson disease (PD) have been frequently implicated in human studies. However, no studies have quantified biomarkers of caffeine intake years before PD onset and investigated whether and which caffeine metabolites are related to PD.

Methods

Associations between self-reported total coffee consumption and future PD risk were examined in the EPIC4PD study, a prospective population-based cohort including 6 European countries. Cases with PD were identified through medical records and reviewed by expert neurologists. Hazard ratios (HRs) and 95% CIs for coffee consumption and PD incidence were estimated using Cox proportional hazards models. A case-control study nested within the EPIC4PD was conducted, recruiting cases with incident PD and matching each case with a control by age, sex, study center, and fasting status at blood collection. Caffeine metabolites were quantified by high-resolution mass spectrometry in baseline collected plasma samples. Using conditional logistic regression models, odds ratios (ORs) and 95% CIs were estimated for caffeine metabolites and PD risk.

Results

In the EPIC4PD cohort (comprising 184,024 individuals), the multivariable-adjusted HR comparing the highest coffee intake with nonconsumers was 0.63 (95% CI 0.46–0.88, p = 0.006). In the nested case-control study, which included 351 cases with incident PD and 351 matched controls, prediagnostic caffeine and its primary metabolites, paraxanthine and theophylline, were inversely associated with PD risk. The ORs were 0.80 (95% CI 0.67–0.95, p = 0.009), 0.82 (95% CI 0.69–0.96, p = 0.015), and 0.78 (95% CI 0.65–0.93, p = 0.005), respectively. Adjusting for smoking and alcohol consumption did not substantially change these results.

Discussion

This study demonstrates that the neuroprotection of coffee on PD is attributed to caffeine and its metabolites by detailed quantification of plasma caffeine and its metabolites years before diagnosis.